scholarly journals Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma

Eye ◽  
2000 ◽  
Vol 14 (1) ◽  
pp. 73-77 ◽  
Author(s):  
Anastasios G P Konstas, ◽  
Athanasios Maltezos ◽  
Theodoros Bufidis ◽  
Alison C Hudgins ◽  
William C Stewart
2020 ◽  
Author(s):  
Ian McWherter ◽  
Meredith Lanham ◽  
Lee Peplinski ◽  
Nikolaos Zagorianos ◽  
Andrew Steele ◽  
...  

Abstract Purpose: To compare the intraocular pressure lowering efficacy of selective laser trabeculoplasty to brimonidine tartrate 0.2%/timolol maleate 0.5% in patients with uncontrolled primary open-angle glaucoma on a prostaglandin analog alone. A secondary outcome was to evaluate the complication rates of selective laser trabeculoplasty.Patients and Methods: Twenty-three patients were randomized to two treatment groups within this prospective, observer-masked single site, all optometrist, pilot study. Group 1 (N=12) received 360 degrees of selective laser trabeculoplasty as additional treatment while Group 2 (N=11) was started on FCBT. Outcomes of both groups were measured at eight weeks.Results: Both treatment regimens were found to be statistically significant in lowering IOP when used as adjunct therapy. The average IOP reduction for Group 1 and Group 2 was 28.4% (SD = .17) and 28.2% (SD = .12) respectively. The incidence of an intraocular pressure spike following SLT in this patient population was found to be 8.3%. No major complications were observed in this study.Conclusion: Selective laser trabeculoplasty and brimonidine tartrate 0.2%/timolol maleate 0.5% were shown to be equivalent in lowering intraocular pressure in uncontrolled primary open angle glaucoma patients when used as adjunct therapy for patients on a prostaglandin analog. Additionally, this is the first prospective study of optometrists performing selective laser trabeculoplasty. Although this study had a small sample size, the results appeared to show that efficacy and complication rates were comparable to previously published data; however, these results need to be confirmed with a larger multi-centered trial.Trial Registration: ISRCTN Study ID ISRCTN30070325, retrospectively registered 12/14/2018. http://www.isrctn.com/ISRCTN30070325.


2019 ◽  
Author(s):  
Ian McWherter ◽  
Meredith Lanham ◽  
Lee Peplinski ◽  
Nikolaos Zagorianos ◽  
Andrew Steele ◽  
...  

Abstract Purpose: To compare the intraocular pressure lowering efficacy of selective laser trabeculoplasty to brimonidine tartrate 0.2%/timolol maleate 0.5% (FCBT, Combigan, Allergan inc. Irvine, CA/USA) in patients with uncontrolled primary open-angle glaucoma on a prostaglandin analog alone. A secondary outcome was to evaluate the complication rates of selective laser trabeculoplasty. Patients and Methods: Twenty-three patients were randomized to two treatment groups within this prospective, observer-masked single site, all optometrist, pilot study. Group 1 (N=12) received 360 degrees of selective laser trabeculoplasty as additional treatment while Group 2 (N=11) was started on FCBT. Outcomes of both groups were measured at eight weeks. Results: Both treatment regimens were found to be statistically significant in lowering IOP when used as adjunct therapy. The average IOP reduction for Group 1 and Group 2 was 28.43% (SD = .17) and 28.22% (SD = .12) respectively. The incidence of an intraocular pressure spike following SLT in this patient population was found to be 8.3%. No major complications were observed in this study. Conclusion: Selective laser trabeculoplasty and brimonidine tartrate 0.2%/timolol maleate 0.5% (FCBT, Combigan, Allergan inc. Irvine, CA/USA) were shown to be equivalent in lowering intraocular pressure in uncontrolled primary open angle glaucoma patients when used as adjunct therapy for patients on a prostaglandin analog. Additionally, this is the first prospective study of optometrists performing selective laser trabeculoplasty. Although this study had a small sample size, the results appeared to show that efficacy and complication rates were comparable to previously published data; however, these results need to be confirmed with a larger multi-centered trial.


e-CliniC ◽  
2016 ◽  
Vol 4 (1) ◽  
Author(s):  
Andrea Lalita ◽  
Yamin Tongku ◽  
J. S. M. Saerang

Abstract: Primary Open Angle Glaucoma (POAG) is the most often type of glaucoma. Glaucoma is one of the most common cause of irreversible blindness worldwide, whereas POAG has nearly 90% of all types of glaucoma. Timolol maleate 0.5% is a non-selective beta adrenergic receptor inhibitor commonly used in the POAG treatment. Mechanism of action of this drug is lowering or suppressing the aquous humor production. The level of intraocular pressure (IOP) reduction in patients with timolol can reach a percentage of 20-30%. This was a retrospective descriptive study. Respondents were POAG patients with timolol maleate 0.5% therapy in the Department of Ophtalmology Prof. Dr. R. D. Kandou Hospital Manado. This study was conducted in November 2015. The results showed that there were 15 respondents who fulfilled the criterias. Of the 15 patients, 8 patients (54%) came for the first control (a week/a month). There were 9 female patients (60%) and 6 male patients (40%). By group of age, the highest percentage was elderly aged 51-60 years (40%). There were 11 patients (74%) with bilateral POAG and only 4 patients (26%) with unilateral POAG. The average percentage of IOP reduction among POAG patients with timolol maleate 0.5% therapy was 16.52%. Conclusion: Among POAG patients with timolol maleate 0.5% therapy there was a 16.52% decrease of the average intraocular pressure in the first control. Keywords: primary open-angle glaucoma, timolol, intraocular pressure Abstrak: Glaukoma Sudut Terbuka Primer (GSTaP) adalah tipe yang paling sering timbul dari penyakit glaukoma. Glaukoma merupakan salah satu penyebab tersering dari kebutaan yang ireversibel di seluruh dunia, dan GSTaP terdapat hampir 90% dari semua tipe penyakit glaukoma. Timolol maleat 0,5% yaitu penghambat reseptor beta adrenergik non selektif merupakan salah satu obat yang paling sering digunakan untuk pengobatan GSTaP. Mekanisme kerja obat ini ialah menurunkan atau supresi produksi humor akuous. Tingkat penurunan TIO (tekanan intraokular) pada pengguna timolol mencapai 20-30%. Penelitian ini bersifat deskriptif retrospektif. Sampel penelitian ialah pasien GSTaP dengan terapi timolol maleat 0,5% di Poliklinik Mata RSUP Prof. Dr. R. D. Kandou Manado. Penelitian ini dilakukan selama bulan November 2015 dengan jumlah sampel 15 orang yang telah memenuhi kriteria penelitian. Hasil penelitian menunjukkan dari 15 pasien tersebut, 8 pasien (54%) datang kembali untuk kontrol (1 minggu/1 bulan pertama). Yang berjenis kelamin perempuan lebih banyak yaitu 9 pasien (60%) sedangkan laki-laki hanya 6 pasien (40%). Berdasarkan kelompok umur, rata-rata umur lansia paling banyak; yang terbanyak yaitu umur 51-60 tahun (40%). Dilihat dari sisi mata, kasus bilateral lebih banyak berjumlah 11 pasien (74%) dibandingkan unilateral hanya 4 pasien (26%). Rerata persentase penurunan TIO pada pasien GSTaP dengan menggunakan terapi timolol maleat 0,5% ialah 16,52%. Simpulan: Pada pasien GSTaP yang diberikan timolol maleat 0,5% terdapat rerata penurunan TIO sebesar 16,52% pada kontrol pertama.Kata kunci: glaukoma sudut terbuka primer, timolol, tekanan intraokular


Sign in / Sign up

Export Citation Format

Share Document